Cadila Healthcare
| Public (: ) | |
| Traded as | BSE:532321 |
| Industry | Pharmaceuticals |
| Founded | 1952 |
| Founder | Ramanbhai Patel |
| Headquarters | Ahmedabad, India |
|
Key people
|
Ramanbhai Patel, Chairman |
| Revenue |
 INR 54.7 Billion (2015) |
|
INR 29.8 Billion (2015) |
|
|
Number of employees
|
13180 (2015) |
| Website | www |
Cadila Healthcare (: ) is an Indian pharmaceutical company headquartered at Ahmedabad in Gujarat state of western India. The company is the fourth largest pharmaceutical company in India, with INR 54.7 Billion revenue (2015). It is a significant manufacturer of generic drugs.
Cadila was founded in 1952 by Ramanbhai Patel (1925–2001), formerly a lecturer in the L.M. College of Pharmacy, and his business partner Bhavya Modi. It evolved over the next four decades into an established pharmaceutical company.
In 1995 the Patel and Modi families split, with the Modi family's share being moved into a new company called Cadila Pharmaceuticals Ltd. and Cadila Healthcare became the Patel family's holding company. Cadila Healthcare had its initial public offering on the in 2000 as stock code 532321.
In 2015 the company acquired another Indian pharmaceutical company called German Remedies. On June 25, 2007, the company acquired Química e Farmacêutica Nikkho do Brasil Ltda (Nikkho) as part of Zydus Healthcare Brasil Ltda.
In 2010, Cadila Healthcare received a Wellcome Trust Award under the "R&D for Affordable Healthcare in India" initiative.
In 2014, Cadila Healthcare launched the world's first adalimumab biosimilar under the brand name Exemptia at one-fifth the originator's price. Zydus Cadila Healthcare has also launched its first research based drug molecule Saroglitazar in treatment of Diabetic Dyslipidemia under brand name "Lipaglyn"
From nine pharmaceutical production operations in India as well as a Zydus Cadila develops and manufactures a large range of pharmaceuticals as well as diagnostics, herbal products, skin care products and other OTC products. Starting from late 2015, having concluded a voluntary license agreement with Gilead, the company also produces the generics for hepatitis C treatment (i.e. sofosbivur, distributed under the brand name SoviHep).
The company makes active pharmaceutical ingredients at three sites in India:
...
Wikipedia